Nanae Tanemura1, Tsuyoshi Sasaki2, Junko Sato3, Hisashi Urushihara4. 1. National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan. n-tanemura@nibiohn.go.jp. 2. Chiba University Hospital, Chiba, Japan. 3. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. 4. Keio University, Tokyo, Japan.
Abstract
BACKGROUND: Incomplete clinical trials for pediatric drug development result in a lack of adequate scientific evidence for providing appropriate medication to pediatric populations; this is especially true for Japan. Thus, using the European Clinical Trials Database (EudraCT), this study aimed to identify the factors related to the study design and administration that lead to incompletion of clinical trials that included pediatric patients. METHODS: We focused on clinical trials that included patients under the age of 18 registered in the database, named as the European Clinical Trials Database between January 1, 2014, and December 31, 2018. Two groups of trials were identified: "all cases completed" and "not all cases completed," reflecting whether they were completed in all participating countries/regions or not. To identify the factors of the occurrence of "not all cases completed," a logistic regression analysis was performed to calculate the odds ratios and 95% confidence intervals. In total, 142 clinical trials (95 "all cases completed" and 47 "not all cases completed") were analyzed. RESULTS: The logistic regression analysis showed the number of countries in which a clinical trial was conducted to be the only significant factor (odds ratio: 1.3; 95% confidence interval: 1.1-1.5); this was identified as the primary factor for the occurrence of "not all cases completed" in the clinical trials that included pediatric patients. CONCLUSION: Our findings suggest that the feasibility of clinical trials that include pediatric patients, such as whether the countries in which the trial is to be conducted are suitable, must be considered prior to the trial.
BACKGROUND: Incomplete clinical trials for pediatric drug development result in a lack of adequate scientific evidence for providing appropriate medication to pediatric populations; this is especially true for Japan. Thus, using the European Clinical Trials Database (EudraCT), this study aimed to identify the factors related to the study design and administration that lead to incompletion of clinical trials that included pediatric patients. METHODS: We focused on clinical trials that included patients under the age of 18 registered in the database, named as the European Clinical Trials Database between January 1, 2014, and December 31, 2018. Two groups of trials were identified: "all cases completed" and "not all cases completed," reflecting whether they were completed in all participating countries/regions or not. To identify the factors of the occurrence of "not all cases completed," a logistic regression analysis was performed to calculate the odds ratios and 95% confidence intervals. In total, 142 clinical trials (95 "all cases completed" and 47 "not all cases completed") were analyzed. RESULTS: The logistic regression analysis showed the number of countries in which a clinical trial was conducted to be the only significant factor (odds ratio: 1.3; 95% confidence interval: 1.1-1.5); this was identified as the primary factor for the occurrence of "not all cases completed" in the clinical trials that included pediatric patients. CONCLUSION: Our findings suggest that the feasibility of clinical trials that include pediatric patients, such as whether the countries in which the trial is to be conducted are suitable, must be considered prior to the trial.
Entities:
Keywords:
Drug development; Pediatric clinical trial; Pediatric investigation plan; Study administration; Study design
Authors: Benjamin Kasenda; Erik von Elm; John You; Anette Blümle; Yuki Tomonaga; Ramon Saccilotto; Alain Amstutz; Theresa Bengough; Joerg J Meerpohl; Mihaela Stegert; Kari A O Tikkinen; Ignacio Neumann; Alonso Carrasco-Labra; Markus Faulhaber; Sohail M Mulla; Dominik Mertz; Elie A Akl; Dirk Bassler; Jason W Busse; Ignacio Ferreira-González; Francois Lamontagne; Alain Nordmann; Viktoria Gloy; Heike Raatz; Lorenzo Moja; Rachel Rosenthal; Shanil Ebrahim; Stefan Schandelmaier; Sun Xin; Per O Vandvik; Bradley C Johnston; Martin A Walter; Bernard Burnand; Matthias Schwenkglenks; Lars G Hemkens; Heiner C Bucher; Gordon H Guyatt; Matthias Briel Journal: JAMA Date: 2014-03-12 Impact factor: 56.272
Authors: Mark A Turner; Sabah Attar; Saskia N de Wildt; Gilles Vassal; Laura Mangiarini; Carlo Giaquinto Journal: Clin Ther Date: 2017-09-22 Impact factor: 3.393
Authors: Nancy A Dreyer; Stella Blackburn; Valerie Hliva; Shahrul Mt-Isa; Jonathan Richardson; Anna Jamry-Dziurla; Alison Bourke; Rebecca Johnson Journal: JMIR Med Inform Date: 2015-04-15